Table 4.

Summary of the adverse events considered in the included economic evaluations.

References	Consideration and description of AEs	Types of AEs
		EPS*	Weight gain	Diabetes	Hyperprolactinemia	Metabolic events**	Others
Einarson et al. (15)	×	×	×	×	×	×	NA
Lachaine et al. (16)	√	√	√	√	×	√	NA
Park et al. (17)	√	√	×	×	√	√	Agranulocytosis
Dilla et al. (18)	√	√	√	×	×	×	Somnolence, sexual dysfunction, postinjection syndrome, suicide
Anh et al. (19)	√	√	√	×	×	×	Agranulocytosis
Lubinga et al. (20)	√	√	√	√	×	×	Ischemic heart disease
Druais et al. (21)	√	√	√	√	×	×	NA
Lin et al. (22)	√	√	√	√	×	×	NA
Rajagopalan et al. (23)	√	√	√	√	×	×	NA
Einarson et al. (24)	×	×	×	×	×	×	NA
Einarson et al. (25)	×	×	×	×	×	×	NA
Barnes et al. (26)	√	√	√	×	×	√	Sexual dysfunction, aversive subjective experience, cardiac symptoms
Einarson et al. (27)	×	×	×	×	×	×	NA
Einarson et al. (28)	×	×	×	×	×	×	NA
Wiwat et al. (29)	√	√	√	√	√	×	NA
Nuhoho et al. (30)	×	×	×	×	×	×	NA
Aigbogun et al. (31)	√	√	√	×	×	√	NA
Németh et al. (32)	√	√	×	×	×	×	NA
Zhao et al. (33)	√	√	√	√	×	√	NA
Abdall-Razak et al. (34)	√	√	√	√	×	×	Diabetes complications: amputation, MI, stroke, IHD, HF
Dutina et al. (35)	√	√	×	×	×	√	Neutropenia
Arteaga et al. (36)	√	√	√	√	√	×	NA
Yi et al. (37)	√	√	√	×	√	√	Liver function damage
Lin et al. (38)	√	√	√	√	√	√	NA
Jin et al. (39)	√	√	√	√		√	Neutropenia

AEs, adverse events; MI, myocardial infarction; IHD, ischemic heart disease; HF, heart failure; NA, not applicable.

^*EPS (effects of the extrapyramidal system) including akathisia, and tardive dyskinesia.

^**Metabolic events including pathoglycemia, dyslipidemia and hypertension.